Lei Fan

Lei Fan

Auto-generated profile, based on publicly available information

Lei Fan

PIESAT Information Technology Co, Ltd, Beijing, 100195, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Natural Hazards Research
Verified
Journal Article
Open access
LCLili Chang
Lili Chang
GXGulian Xing
Gulian Xing
HYHui Yin
Hui Yin
LFLei Fan
Lei Fan
RZRui Zhang
Rui Zhang
JMJuan Ma
Juan Ma

28 November 2022 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
JLJianxiu Lu
Jianxiu Lu
WWWenjuan Wang
Wenjuan Wang
ZXZe Xu
Ze Xu
PZPeiying Zhang
Peiying Zhang
JGJiake Gu
Jiake Gu
LFLei Fan
Lei Fan

1 January 2023 in Food Science of Animal Resources
Verified
Journal Article
Open access
PDF file
HGHao Guo
Hao Guo
LFLei Fan
Lei Fan
LDLin Ding
Lin Ding
WYWenqin Yang
Wenqin Yang
CZChuangang Zang
Chuangang Zang
HGHong Guan
Hong Guan
Food Science of Animal Resources (Food Sci. Anim. Resour.) is an international, peer-reviewed bimonthly journal publishing original research and reviews on basic and applied aspects of the use of animal resources including the meat, egg, dairy, and edible insect/worm products. Food Sci. Anim. Resour. is published and distributed by the Korean Society for Food Science of Animal Resources.

1 July 2022 in Annals of Palliative Medicine
Verified
Journal Article
Open access
PDF file
LLLei Lei
Lei Lei
RCRucheng Chen
Rucheng Chen
LFLei Fan
Lei Fan
WZWeijun Zheng
Weijun Zheng
XWXiaojia Wang
Xiaojia Wang
Background: Long-term benefit of nanoparticle-albumin-bound paclitaxel (Nab-P) over conventional taxanes in breast cancer patients is still controversial. We conducted a systematic review of studies to identify the optimal taxanes for selection in clinical practice. Methods: We enrolled studies if they enrolled adults (age ≥18) with breast cancer, compared Nab-P (at any dose) to conventional paclitaxel or docetaxel, provided information on survival data, the response rate, or adverse events, were randomized controlled trials, case-control studies, or cohort studies, and were published in English (including those published online, ahead of the print publication). Cochrane Collaboration tool and Newcastle-Ottawa scale were used for bias-risk assessment. Grading of recommendations assessment, development, and evaluation approach were adopted for the quality of evidence evaluation. The outcomes included the overall response rate, pathological complete response rate, progression-free survival, overall survival, allergic reaction, leukopenia, neutropenia, and sensory neuropathy. Results: A total of 20 eligible clinical studies comprising 11,046 patients were included in the analysis. No significant publication bias was observed based on a visual inspection of the funnel plots for progressionfree survival (PFS), and overall survival (OS). Compared to the conventional taxanes group (n=2,743), the Nab-P group (n=1,680) had a significantly higher ORR (RR =1.21, 95% CI: 1.07–1.37; P=0.003) and pCR (RR =1.33, 95% CI: 1.17–1.51; P<0.001). The Nab-P group also had a lower risk of disease progression and death than the conventional taxanes group (HR =0.89, P=0.269). Additionally, the Nab-P group had fewer treatment-related allergic reactions (RR =0.74, 95% CI: 0.59–0.93; P=0.009) and less grade ≥4 neutropenia (RR =0.39, 95% CI: 0.20–0.77; P=0.007) than the conventional taxanes group. The incidence of any-grade of neutropenia and sensory neuropathy were significantly higher in the Nab-P group than the conventional taxanes group (P=0.009 and P<0.001, respectively). Discussion: The Nab-P in all stages of breast cancer patients had significantly better efficacy and tolerance than the conventional taxanes. Moreover, preventive strategies for reducing the incidence of Nab-P induced sensory neuropathy should be explored in future studies.